Belgium-based UCB hit the mark in the company’s Phase III clinical trial assessing zilucoplan as a potential treatment for adults with generalized myasthenia gravis, a rare autoimmune disease. Vanda Pharmaceuticals’ late-stage study of tradipitant as a treatment for the symptoms of gastroparesis, a digestive disorder, failed to meet the trial’s primary endpoint.

The Omicron variant appears to result in less severe COVID-19 than seen during previous periods of high coronavirus transmission including the Delta wave, with shorter hospital stays, less need for intensive care and fewer deaths, according to a new U.S. study.

The risk of hospitalization with the Omicron variant of coronavirus is about one-third that of the Delta variant, according to British analysis of more than a million cases of both types in recent weeks.

The U.S. Food and Drug Administration on Oct. 12 allowed British American Tobacco Plc to market the company’s Vuse Solo e-cigarettes and tobacco-flavored pods, the first-ever vapor product to get clearance from the health regulator.

Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.

Data and AI scientists must strive to eliminate bias from anything that touches patient care.

Pfizer’s Covid-19 vaccine greatly reduces virus transmission, according to two Israeli studies, shedding light on one of the biggest questions of the global effort to quash the pandemic.

An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.

EVERSANA announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments.

EVERSANA, a leading independent provider of global commercial services to the life sciences industry, announced the appointment of Brigham Hyde, Ph.D. to President, Data & Analytics (D&A).